Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Clinical and Translational Science|April 26, 2022
A literature review of liver function test elevations in rifampin drug-drug interaction studiesSherry M Ibrahim, Yazdi K Pithavala, Manoli Vourvahis, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 15, 2021
Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participantsJoseph Chen, Brett Houk, Yazdi K Pithavala, et al.
Journal of Clinical Pharmacology|April 4, 2022
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) InhibitionSteven Sun, Yazdi K Pithavala, Jean-François Martini, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2025
Landscape analysis of adverse events and dose intensity for FDA approved oncology small moleculesKeagan P Collins, Donghua Yin, Yazdi K Pithavala, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteersPoe-Hirr Hsyu, Yazdi K Pithavala, Merril Gersten, et al.
British Journal of Clinical Pharmacology|July 10, 2013
Population pharmacokinetic analysis of axitinib in healthy volunteersMay Garrett, Bill Poland, Meghan Brennan, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2021
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participantsJennifer E Hibma, Melissa O'Gorman, Sunil Nepal, et al.
Clinical Pharmacokinetics|March 12, 2026
Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction ModelDerek Z Yang, Erik M Hahn, Joseph Piscitelli, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 19, 2014
Common questions regarding clinical use of axitinib in advanced renal cell carcinomaDiane L Borst, Lillian S Arruda, Elizabeth MacLean, et al.
Clinical Pharmacokinetics|October 26, 2014
Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinomaYing Chen, Brian I Rini, Angel H Bair, et al.
Pageof 4